Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (October 2014)
35 slides from Anatara Lifesciences's investor presentation, Oct 22, 2014
Slide 1: About Anatara Lifesciences
ASX Release For personal use only About Anatara Lifesciences
Slide 2: Oral solutions for gastrointestinal disease: Detach
For personal use only Oral solutions for gastrointestinal disease DetachTM – prevention and treatment of diarrhoea 20 October 2014
Slide 3: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 4: Anatara Investment Overview
Anatara Investment Overview For personal use only • Experienced Board and management team with proven track record • Lead product, DetachTM has a clear route to market: - Commercially validated and proven efficacy - Development strategy de-risked and revenues within 2 years • Product pipeline – anim
Slide 5: Antimicrobial resistance is a serious health problem
For personal use only Antimicrobial resistance is a serious health problem Many antibiotics are no longer effective, so bacterial infections are more difficult to treat. “23,000 people die every year from antibiotic-resistant infections in US” The US Center for Disease Control “Combat drug resistanc
Slide 6: Need to combat antimicrobial resistance
Need to combat antimicrobial resistance For personal use only • Antimicrobial resistance is a worldwide threat to public health – WHO, CDC • The spread of bacteria that are resistant to antibiotics -“Super Bugs”- is driven by antibiotic overuse — in man and animals. • Authorities around the world ar
Slide 7: Detach
For personal use only Detach™ • Non-antibiotic solution that prevents and treats diarrhoea • Meets the need to reduce antibiotics in animal production • Based on a proven product, that improves animal health and farming economics
Slide 8: Detach - poised for swift return
Detach™ - poised for swift return For personal use only • In 1991 DetachTM gained 40% market penetration (marketed by Ciba Geigy) • Leverage extensive data available on former product to fast track development of DetachTM through the Australian regulators (APVMA) • Clear path to market • Launch plan
Slide 9: Human vs Animal: Faster and Cheaper route to Market
Human vs Animal: Faster and Cheaper route to Market For personal use only On average, it takes 53% more time and is 97.3% more costly to bring human drugs to market, than animal drugs Market Detach Approval is here ~7 years 0 3 6 9 12 15 years Pre‐clinical/ Development Reg’n Marketing Formulation Di
Slide 10: Summary of field trials 1988-1991
Summary of field trials 1988-1991 For personal use only Detach proven to be safe and effective in several thousand piglets. Detach reduced death, improved weight gains and reduced antibiotic use. Detach increased farmer returns Trial Summary Pre-Weaner Weaner Number of Trials 11 8 Number of Piglets
Slide 11: Detach – Effective in New Field Trials - 2012
DetachTM – Effective in New Field Trials - 2012 For personal use only • New formulation of DetachTM trialled in weaner piglets on a commercial pig farm in Spain (n = 288) • DetachTM reduced the incidence of post- weaning scour by 40% compared to untreated pigs • Detach improved average daily weight
Slide 12: Detach – Improves FCR in new trials - 2012
DetachTM – Improves FCR in new trials - 2012 For personal use only • The cost of feed is the major cost to pork production accounting for up to 80% of all production expenses. • Every improvement in FCR will reduce feed costs and improve profitability. Field Study Comparisons Improvement in FCR (%)
Slide 13: Science
For personal use only Science Well validated mechanism of action Published in high impact academic journals World class scientific collaborators
Slide 14: Detach Triple Mechanism of Action
Detach™ Triple Mechanism of Action = Broad Spectrum Activity For personal use only Effective against diarrhoea caused by bacteria, viruses and parasites 2. Blocks toxin action 3. Blocks inflammatory action. 1. Prevents attachment of bacteria Detach Detach
Slide 15: Intellectual Property
Intellectual Property For personal use only • 1991 – Rights to the original successful product and all data owned by Anatara • 2012 – Former product re-formulated. DetachTM has reduced cost of goods, and improved convenience for farmers • 2014 - USA patent filed • Solid patent strategy in place for
Slide 16: Detach - Key Benefits
Detach™ - Key Benefits For personal use only • Detach™ is an orally administered, natural, non-antibiotic treatment for diarrhoea • Detach™ is safe - active ingredient is an extract from pineapple stems • Detach™ is broad acting – works against bacteria, virus and parasites • Detach™ improves animal
Slide 17: Pork CRC commitment to reduce antimicrobial use
For personal use only The Pork CRC has committed to reduce antimicrobial use by 50% within 5 years. Australian Senate Report, August 2013.
Slide 18: Significant market opportunity
Significant market opportunity For personal use only • Growing awareness of urgent need to address antimicrobial resistance • Demand for non-antibiotic treatments will rise as authorities act to restrict use of antibiotics in farm animals • Hundreds of millions of pigs born every year are affected b
Slide 19: Consumer Pressure - Food Quality & Food Safety
Consumer Pressure - Food Quality & Food Safety For personal use only 18
Slide 20: Diarrhoea affects hundreds of millions of pigs born each year
Diarrhoea affects hundreds of millions of pigs born each year For personal use only
Slide 21: Commercialisation strategy
Commercialisation strategy For personal use only Livestock • Market - Anatara will market Detach™ in Australia directly to pork producers • Supply - DetachTM will be supplied via pre- existing distribution channels • Partner - Co-development and commercialisation partners in discussion for Detach™ i
Slide 22: Detach for Humans
For personal use only Oral solutions for gastrointestinal disease DetachTM for Humans
Slide 23: Detach for Humans: overview
DetachTM for Humans: overview For personal use only • Unmet Need – Diarrhoea is a major unmet need for travellers, the military and in the developing world. • Status – Safe - DetachTM for humans has completed Phase I studies. – Pre-clinical efficacy database is very strong due to leverage of DetachT
Slide 24: From Animals to Humans
Oral Solutions for Gastrointestinal Disease: From Animals to Humans For personal use only Pigs Discovery Pre‐Clinical & Clinical Reg Market People Clinical – Phase I, II and III Reg’n Marketing Detach – From Pigs to People Pre-clinical complete therefore development de-risked Revenue already secured
Slide 25: Development Milestones
Development Milestones For personal use only Activity 2014 2015 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Detach for Pigs : Australia Launch Launch Detach for Pigs : Europe Detach for Pigs : USA Launch Detach For Humans Partner
Slide 26: Use of Funds
Use of Funds For personal use only 3 year Operating Costs: Development Program Costs: Detach For Pigs – Australia funded Detach For Pigs – EU $1,055,000 Detach For Pigs ‐ USA $730,000 Detach for Humans $392,000 Corporate: Salaries, Board & Administration: $3,712,000 Patents $300,000 Offer Costs $811
Slide 27: Capital structure
Capital structure For personal use only Offer Details Offer Price Per Share $0.50 Shares available under the IPO 14,000,000 % of the Company 37.1% Total Cash Proceeds of the Offer $7,000,000 Shares on Issue before the Offer1 23,750,000 Total Shares on Issue on Completion of the Offer2 37,750,000 Mar
Slide 28: Indicative timetable
Indicative timetable For personal use only ASX code is ANR Item Timetable Prospectus date 29th August 2014 Offer opens 12th September 2014 Offer closes 3rd October 2014 ASX trading 16th October 2014 All dates and times are subject to change and are indicative only. All times are Australian Eastern S
Slide 29: Board of Directors
Board of Directors For personal use only Dr Melvyn Bridges PhD – Chairman Mel has over 30 years’ experience building successful, international life science, diagnostic and medical device companies. Founder, Chairman and Director of ASX, FTSE and NASDAQ companies. Mr Iain Ross – Director Former senio
Slide 30: Experienced Management
Experienced Management For personal use only Dr David Venables PhD – CEO & Managing Director Experienced CEO, Director and senior manager of international life science companies, with extensive development and manufacturing experience. Successfully launched new vaccine products and built manufacturi
Slide 31: Anatara: 2014 Milestones Achieved
Anatara: 2014 Milestones Achieved For personal use only Financing • Successful seed fund raising (oversubscribed) Manufacture • GMP Manufacturing Agreement in place Field Trials • Contracts in place for Field Trials Regulatory • Regulatory pathway confirmed for Australia, EU and USA • Successful mee
Slide 32: Anatara investment case
Anatara investment case For personal use only • Experienced Board and management team with proven track record • Lead product, DetachTM has a clear route to market: - Commercially validated and proven efficacy - Development strategy de-risked and revenues within 2 years • Product pipeline – animal p
Slide 33: Thank you
For personal use only Thank you “With the world’s meat production needs set to rise 100% by 2050, it is important we act now to develop non-antibiotic treatment options.” Mel Bridges, Chairman – Anatara Lifesciences
Slide 34: Contact details
Contact details For personal use only ANATARA COMPANY CONTACTS David Venables, CEO Tracey Mynott, CSO dvenables@anataralifesciences.com tmynott@anataralifesciences.com +44 (0) 141 628 6008 +61 405 050 113 MEDIA AND INVESTOR RELATIONS Jane Lowe, Buchan Consulting jlowe@buchanwe.com.au +61 2 9237 2800
Slide 35: Competition and Limitations
Competition and Limitations For personal use only Description Example Limitations Ciprofloxacin, Contributes to AMR/residues Antibiotics Azithromycin, Rifaximin Pathogen specific ($0.31 to $1.22/pig) Antimicrobial resistance Zinc Oxide Antimicrobial (widely used although not Environmental issues/res
Anatara Lifesciences — Investor Presentation (October 2014) on 6ix